Related Experiment Videos
Circulating thymic hormone activity in young cancer patients
Clinical and Experimental Immunology
|October 1, 1986
Summary
Young cancer patients often have low serum levels of Facteur Thymique Sérique (FTS), a thymic hormone crucial for immune surveillance. Inhibitory factors in their plasma may further impact FTS activity, suggesting therapeutic monitoring is important.
Area of Science:
- Immunology
- Pediatric Oncology
- Endocrinology
Background:
- Facteur Thymique Sérique (FTS) is a thymic hormone involved in immune regulation.
- Altered FTS levels have been implicated in various diseases, including cancer.
Purpose of the Study:
- To investigate serum FTS levels in young cancer patients.
- To explore potential factors affecting FTS activity in this population.
Main Methods:
- Serum FTS levels were measured in 56 young cancer patients and compared to normal controls.
- In vitro assays were performed to detect inhibitors of FTS biological activity in patient plasma.
Main Results:
- Young cancer patients, particularly those on immunosuppressive therapy, exhibited low age-corrected FTS titres.
- Low FTS levels were observed at diagnosis and during periods off therapy.
- Plasma from 22 patients contained factors inhibiting FTS activity in vitro.
- No zinc deficiency was detected, suggesting FTS is secreted in an active form.
Conclusions:
- Monitoring FTS activity is crucial in young cancer patients due to its implications for immunological surveillance.
- The presence of FTS inhibitors warrants further investigation.
- Thymic hormone therapy may have practical applications in managing cancer patients.